Immune Thrombocytopenia historical perspective

Revision as of 02:36, 20 January 2021 by Maryam Barkhordarian (talk | contribs) (ITP perspective history)
Jump to navigation Jump to search

Immune Thrombocytopenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Immune Thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Immune Thrombocytopenia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Immune Thrombocytopenia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Immune Thrombocytopenia historical perspective

CDC on Immune Thrombocytopenia historical perspective

Immune Thrombocytopenia historical perspective in the news

Blogs on Immune Thrombocytopenia historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Immune Thrombocytopenia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]

Overview

Historical Perspective

Discovery

  • There is limited information about the historical perspective of [disease name].

OR

  • Idiopathic Thrombocytopenia was first described by a German poet Paul Werlhof, in 1735. He referred to classical signs of ITP as mucosal bleeding, black and purple spots on the patient's arm, due to this description, ITP is called Werlhof's disease.
  • The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
  • In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
  • In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

Landmark Events in the Development of Treatment Strategies

Impact on Cultural History

Famous Cases

The following are a few famous cases of [disease name]:

References

Template:WH Template:WS